MCVE.Y Stock Overview
Provides healthcare and diagnostic services in Poland, Sweden, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Medicover AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 16.55 |
| 52 Week High | SEK 16.55 |
| 52 Week Low | SEK 16.55 |
| Beta | 1.38 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 90.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| MCVE.Y | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | -5.1% | -2.1% |
| 1Y | n/a | 3.0% | 29.7% |
Return vs Industry: Insufficient data to determine how MCVE.Y performed against the US Healthcare industry.
Return vs Market: Insufficient data to determine how MCVE.Y performed against the US Market.
Price Volatility
| MCVE.Y volatility | |
|---|---|
| MCVE.Y Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 6.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MCVE.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MCVE.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 38,000 | Fredrik Rågmark | www.medicover.com |
Medicover AB (publ) provides healthcare and diagnostic services in Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It operates through two segment, Healthcare Services and Diagnostic Services. The company’s diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology.
Medicover AB (publ) Fundamentals Summary
| MCVE.Y fundamental statistics | |
|---|---|
| Market cap | US$2.17b |
| Earnings (TTM) | US$60.86m |
| Revenue (TTM) | US$1.49b |
35.6x
P/E Ratio1.5x
P/S RatioIs MCVE.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MCVE.Y income statement (TTM) | |
|---|---|
| Revenue | €1.46b |
| Cost of Revenue | €1.08b |
| Gross Profit | €370.50m |
| Other Expenses | €310.90m |
| Earnings | €59.60m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 03, 2022
| Earnings per share (EPS) | 0.40 |
| Gross Margin | 25.46% |
| Net Profit Margin | 4.10% |
| Debt/Equity Ratio | 91.4% |
How did MCVE.Y perform over the long term?
See historical performance and comparison